Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
McKesson
Baxter
Mallinckrodt
Harvard Business School

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XARELTO

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Xarelto

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00831714 Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty Completed Bayer N/A 2009-02-01 The main goal is to provide additional information to the risk-benefit assessment of the drug.
NCT01029743 Xarelto Regulatory Post-Marketing Surveillance Completed Bayer N/A 2009-12-01 This study is to identify the following problems and questions with respect to the safety and effectiveness of Xarelto in comparison with other pharmacologic agents in the prophylaxis of venous thromboembolism (VTE) in a large sample of patients who undergo elective total hip replacement (THR) or total knee replacement (TKR) in the real-life conditions in its registered indication(s) as required by Korean Food and Drug Administration (KFDA). 1. Known and unknown adverse reactions, especially serious adverse reactions 2. Incidence of adverse reactions under the routine drug use 3. Factors that may affect the safety of the drug 4. Factors that may affect the effectiveness of the drug 5. Other safety information related to overuse, drug interaction and laboratory abnormalities 6. Other adverse reactions
NCT01210755 Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics Completed University Hospital, Grenoble Phase 4 2010-11-01 The purpose of this study is to evaluate whether the effect of the two new anticoagulants, Dabigatran and Rivaroxaban, can be reversed by non-specific and specific inhibitors. For Dabigatran the investigators will test the non-specific inhibitors: prothrombin complex concentrate (PCC), recombinant activated coagulation factor VII, and activated prothrombin-complex (FEIBA). For Rivaroxaban the investigators will test a specific Rivaroxaban decoy (FXa-GLAless). This will be done in a laboratory using blood plasma from healthy male volunteers.
NCT01344954 Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery Completed BioInvent International AB Phase 2 2011-04-01 The purpose of this study is to evaluate the safety and efficacy of two doses of TB-402 administered as a single intravenous infusion for the prevention of VTE in subjects undergoing total hip replacement surgery.
NCT01344954 Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery Completed ThromboGenics Phase 2 2011-04-01 The purpose of this study is to evaluate the safety and efficacy of two doses of TB-402 administered as a single intravenous infusion for the prevention of VTE in subjects undergoing total hip replacement surgery.
NCT01444586 Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) Completed Bayer N/A 2011-10-01 This is a local, prospective, multicenter, non-interventional, observational study. Primary objective is to describe how in "real life" thromboprophylaxis is carried out after the discharge from a hospital in the patients who undergo elective knee and hip replacement and who receive Xarelto during hospitalization.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xarelto

Condition Name

Condition Name for Xarelto
Intervention Trials
Atrial Fibrillation 21
Venous Thromboembolism 15
Venous Thrombosis 6
Deep Vein Thrombosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Xarelto
Intervention Trials
Thrombosis 25
Atrial Fibrillation 25
Thromboembolism 24
Venous Thromboembolism 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Xarelto

Trials by Country

Trials by Country for Xarelto
Location Trials
United States 61
Canada 30
China 11
Germany 10
France 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Xarelto
Location Trials
Florida 5
North Carolina 5
California 5
Illinois 4
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Xarelto

Clinical Trial Phase

Clinical Trial Phase for Xarelto
Clinical Trial Phase Trials
Phase 4 30
Phase 3 27
Phase 2/Phase 3 3
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Xarelto
Clinical Trial Phase Trials
Recruiting 32
Not yet recruiting 25
Completed 25
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Xarelto

Sponsor Name

Sponsor Name for Xarelto
Sponsor Trials
Bayer 30
Janssen Research & Development, LLC 4
Second Affiliated Hospital, School of Medicine, Zhejiang University 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Xarelto
Sponsor Trials
Other 156
Industry 50
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Baxter
Harvard Business School
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.